참고문헌
- Brozovic, A. and Osmak, M. : Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatinresistance. Cancer Lett. 251, 1 (2007)
- Siddik, Z. H. : Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22, 7265 (2003)
- Kartalou, M. and Essigmann, J. M. : Mechanisms of resistance to cisplatin. Mutat Res. 478, 23 (2001) https://doi.org/10.1016/S0027-5107(01)00142-7
- Fojo, T. and Bates, S. : Strategies for reversing drug resistance. Oncogene. 22, 7512 (2003)
- Kobayashi, M. and Yamamoto, M. : Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal. 7, 385 (2005)
- Kensler, T. W., Wakabayashi, N. and Biswal, S. : Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89 (2007)
- Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., Harada, T., Engel, J. D. and Yamamoto, M. : Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238 (2003)
- Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D. and Yamamoto, M. : Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13, 76 (1999)
- Kwak, M. K., Wakabayashi, N. and Kensler, T. W. : Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat. Res. 555, 133 (2004) https://doi.org/10.1016/j.mrfmmm.2004.07.012
- Cho, H. Y., Reddy, S. P. and Kleeberger, S. R. : Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal. 8, 76 (2006)
- Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., Brock, M. V. and Biswal, S. : Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006)
- Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M. I., Kobayashi, A., Yokoyama, S. and Yamamoto, M. : Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell. 21, 689 (2006)
- Kwak, M. K., Wakabayashi, N., Greenlaw, J. L., Yamamoto, M. and Kensler, T. W. : Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway. Mol. Cell Biol. 23, 8786 (2003) https://doi.org/10.1128/MCB.23.1.1-13.2003
- Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. : Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47, 936 (1987)
- Lewandowicz, G. M., Britt, P., Elgie, A. W., Williamson, C. J., Coley, H. M., Hall, A. G. and Sargent, J. M. : Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol Oncol. 85, 298 (2002)
- Cho, J. M., Manandhar, S., Lee, H. R., Park, H. M. and Kwak, M. K. : Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Lett. 260, 96 (2008)
- Stacy, D. R., Ely, K., Massion, P. P., Yarbrough, W. G., Hallahan, D. E., Sekhar, K. R. and Freeman, M. L. : Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 28, 813 (2006)
- Kwak, M. K., Kensler, T. W. and Casero, R. A. Jr. : Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2: effect of the polyamine metabolite acrolein. Biochem. Biophys. Res. Commun. 305, 662 (2003)
- Rappa, G., Gamcsik, M. P., Mitina, R. L., Baum, C., Fodstad, O. and Lorico, A. : Retroviral transfer of MRP1 and gammaglutamyl cysteine synthetase modulates cell sensitivity to Lbuthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Eur. J. Cancer. 39, 120 (2003)
- Iida, T., Kijima, H., Urata, Y., Goto, S., Ihara, Y., Oka, M., Kohno, S., Scanlon, K. J. and Kondo, T. : Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer. Gene Ther. 8, 803 (2001)